FSTL1 and metabolic dysfunction-associated steatohepatitis: Our data thus strongly suggested a model in which skeletal muscle IRF4 transcriptionally regulates FSTL1, and the latter is secreted in the liver to mediate liver metabolism through DIP2A/CD14, eventually affecting the pathology of NASH (Fig. 7j).